“Meta-guidelines” for the management of patients with schizophrenia

CNS Spectrums

Volumn 18, Issue 3, 2013, Pages 150-162

  Stahl, Stephen M ^a,b,c,d   Morrissette, Debbi A ^c   Citrome, Leslie ^e   Saklad, Stephen R ^f,g,h   Cummings, Michael A ^d   Meyer, Jonathan M ^a,d   O'day, Jennifer A ^d   Dardashti, Laura J ^d   Warburton, Katherine D ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^d CA State Dept of Health Services   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

acute; antipsychotics; Assessment; depot; maintenance

Indexed keywords

NEUROLEPTIC AGENT;

ACUTE DISEASE; CASE MANAGEMENT; HOSPITALIZATION; HUMAN; META ANALYSIS; PATIENT CARE PLANNING; PRACTICE GUIDELINE; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; CASE MANAGEMENT; GUIDELINES AS TOPIC; HOSPITALIZATION; HUMANS; PATIENT CARE PLANNING; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

MLCS; MLOWN;

EID: 84881244806     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S109285291300014X     Document Type: Article

References (16)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Washington, DC: American Psychiatric Association; 2004.
2. American Psychiatric Association. Treating Schizophrenia: A Quick Reference Guide. Washington, DC: American Psychiatric Association; 2004.
3. Kane JM, Leucht S, Carpenter D,, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003; 64(suppl 12): 5–19. 10.4088/JCP.v64n0301
4. Moore TA, Buchanan RW, Buckley PF,, et al. The Texas Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007; 68(11): 1751–1762. 10.4088/JCP.v68n1115 18052569
5. Dixon L, Perkins D, Calmes C. Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Association; 2009.
6. Buchanan RW, Kreyenbuhl J, Kelly DL,, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 71–93. 10.1093/schbul/sbp116 19955390
7. Dixon LB, Dickerson F, Bellack AS,, et al. The 2009 PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 48–70. 10.1093/schbul/sbp115 19955389
8. Kreyenbuhl J, Buchanan RW, Dickerson FB,, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010; 36(1): 94–103. 10.1093/schbul/sbp130 19955388
9. Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand. 2010; 122: 440–441. 10.1111/j.1600-0447.2010.01606.x 20880158
10. Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125: 349–351. 10.1111/j.1600-0447.2012.01841.x 22506490
11. Stahl SM. The tyranny of the majority and the interchangeability of drugs. Acta Psychiatr Scand. 2013; 127: 4–5. 10.1111/acps.12025 23240592
12. Stahl SM, Morrissette DA. Should high dose or very long term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice, Volume I: Use of Polypharmacy in the “Real World”. Dordrecht, The Netherlands: Springer Science; 2013.
13. Ritsner MS, ed. Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies. Dordrecht, The Netherlands: Springer Science; 2013.
14. Ritsner MS, ed. Polypharmacy in Psychiatry Practice, Volume 2: Use of Polypharmacy in the “Real World.” Dordrecht, The Netherlands: Springer Science; 2013.
15. Stahl SM. Stahl's Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.
16. National Institutes of Mental Health Psychoactive Drug Screening Program. http://pdsp.med.unc.edu/indexR.html. Accessed August 2012.